Actively Recruiting
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2026-01-12
400
Participants Needed
2
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
CONDITIONS
Official Title
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and voluntarily provide written informed consent
- Patients with histologically or cytologically confirmed unresectable solid tumors
- At least one measurable lesion per RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Adequate organ functions as defined in the protocol
- Minimum life expectancy of 3 months
You will not qualify if you...
- Known active central nervous system (CNS) metastases
- History of other malignancy within the past 5 years except as defined in the protocol
- Uncontrolled cancer pain
- Serious cardiovascular and/or cerebrovascular diseases
- Uncontrollable third-space effusions such as pleural, pericardial, or peritoneal effusion
- Severe infections within 4 weeks before first dose
- Active pulmonary tuberculosis infection
- History of immunodeficiency
- History of autoimmune diseases
- Previous antineoplastic therapy adverse events not recovered to CTCAE grade 1 or less
- Pregnant or nursing women, or planning pregnancy during the study
- Known allergy to any component of investigational drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
2
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
Research Team
X
Xianhua Qiu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here